GlobeNewswire·Nov 9, 2026, 4:01 PM ET

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

Enrollment continues in the global Phase 3 ALPACCA trial evaluating firmonertinib for first-line EGFR PACC mutant NSCLC.
The Phase 3 FURVENT study did not meet its primary endpoint of progression-free survival by blinded independent central review, though firmonertinib showed median PFS of 11.0 months versus 9.5 months with chemotherapy.
Preliminary Phase 1 data for the CDH17-targeted ADC ARR-217 presented at ESMO showed a 44.8% objective response rate in colorectal cancer patients.
The first patient was dosed in the U.S. Phase 1a/1b study of ARR-002, a dual-target MUC16/NaPi2b ADC, focusing on ovarian and endometrial cancers.
Dr. Priti Patel was appointed as Chief Medical Officer to lead clinical development, while co-founder Dr. Stuart Lutzker announced his retirement.
Cash and investments totaled $393.2 million as of September 30, 2026, expected to fund operations through mid-2028.
Net loss for the nine months ended September 30, 2026, was $133.5 million, with research and development expenses of $118.9 million.
Firmonertinib updates regarding the FURVENT study review are planned for the first quarter of 2027.
ARR-217 Phase 1b dose optimization data is expected in the first half of 2027, with combination data anticipated in the second half.